Fig. 1: Schematic diagram of patients selection, enrollment, and study design. | Nature Communications

Fig. 1: Schematic diagram of patients selection, enrollment, and study design.

From: ZSP1601, a novel pan-phosphodiesterase inhibitor for the treatment of NAFLD, A randomized, placebo-controlled phase Ib/IIa trial

Fig. 1

A total of 95 NASH patients were screened, of which 37 patients were randomized, and 36 NAFLD patients were enrolled in three cohorts. Each cohort included 12 patients, 9 of whom received ZSP1601 50 mg QD, 50 mg BID, or 100 mg BID, and 3 of whom received matching placebos for 28 days. All the 36 patients completed the clinical trial and were scheduled to receive a 14-day treatment-free follow-up.

Back to article page